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Abstract
Background: Several clinical studies have suggested that N-acetylaspartate and N-acetylaspartylglutamate levels in the human 
brain are associated with various psychiatric disorders, including major depressive disorder. We have previously identified 
Shati/Nat8l, an N-acetyltransferase, in the brain using an animal model of psychosis. Shati/Nat8l synthesizes N-acetylaspartate 
from L-aspartate and acetyl-coenzyme A.  Further, N-acetylaspartate is converted into N-acetylaspartylglutamate, a 
neurotransmitter for metabotropic glutamate receptor 3.
Methods: Because Shati/Nat8l mRNA levels were increased in the dorsal striatum of mice following the exposure to forced 
swimming stress, Shati/Nat8l was overexpressed in mice by the microinjection of adeno-associated virus vectors containing 
Shati/Nat8l gene into the dorsal striatum (dS-Shati/Nat8l mice). The dS-Shati/Nat8l mice were further assessed using 
behavioral and neurochemical tests.
Results: The dS-Shati/Nat8l mice exhibited behavioral despair in the forced swimming and tail suspension tests and social 
withdrawal in the 3-chamber social interaction test. These depression-like behaviors were attenuated by the administration of 
a metabotropic glutamate receptor 2/3 antagonist and a selective serotonin reuptake inhibitor. Furthermore, the metabolism 
of N-acetylaspartate to N-acetylaspartylglutamate was decreased in the dorsal striatum of the dS-Shati/Nat8l mice. This 
finding corresponded with the increased expression of glutamate carboxypeptidase II, an enzyme that metabolizes N-
acetylaspartylglutamate present in the extracellular space. Extracellular serotonin levels were lower in the dorsal striatum of 
the dS-Shati/Nat8l and normal mice that were repeatedly administered a selective glutamate carboxypeptidase II inhibitor.
Conclusions: Our findings indicate that the striatal expression of N-acetylaspartate synthetase Shati/Nat8l plays a role in major 
depressive disorder via the metabotropic glutamate receptor 3-mediated functional control of the serotonergic neuronal system.
Keywords: Shati/Nat8l, behavioral despair, social withdrawal, mGluR3, serotonin
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Introduction
The worldwide increase in the number of patients with psychiat-
ric disorders, such as major depressive disorder, autism spectrum 
disorder, schizophrenia, and bipolar disorder, has garnered sig-
nificant attention. However, current medical treatments for these 
disorders have notable limitations. In particular, the antidepres-
sants that are widely prescribed for major depressive disorder, 
which affects approximately 16% of the population (Kupfer et al., 
2012) and has an age of onset that encompasses the entire lifes-
pan (Kessler et al., 2007), require 2 to 3 weeks to produce thera-
peutic benefits and are only moderately effective. Furthermore, a 
portion of these patients is resistant to these therapeutic drugs 
(Trivedi et al., 2006). A functional insertion deletion promoter var-
iant in the serotonin (5-hydroxytryptamine [5-HT]) transporter 
gene SLC6A4 (Huezo-Diaz et  al., 2009; Wilkie et  al., 2009; Kato 
and Serretti, 2010) may explain the inefficient outcome of these 
medical treatments. Therefore, additional studies are required 
to understand the pathophysiology of major depressive disorder 
and develop new therapeutic strategies.
Shati was isolated from the brain of animals with metham-
phetamine-induced psychosis (Niwa et al., 2007). Shati was later 
identified as an N-acetyltransferase-8 like protein (Nat8l) that 
catalyzes N-acetylaspartate (NAA) synthesis from aspartate and 
acetyl-coenzyme A (Ariyannur et al., 2010). Thus, we refer to this 
enzyme as Shati/Nat8l in the present study. NAA exists at high 
levels in the human brain (Moffett et al., 1991) and is condensed 
with glutamate and converted into N-acetylaspartylglutamate 
(NAAG) by NAAG synthetase (NAAGS) (Becker et al., 2010). NAAG 
is widely distributed in the brains of mammals (Moffett and 
Namboodiri 1995; Passani et al., 1997; Neale et al., 2000) and acts 
as a highly selective neurotransmitter for group II metabotropic 
glutamate receptor 3 (mGluR3) (Neale et al., 2011). Following the 
release of NAAG into the synaptic cleft, NAAG binds mGluR3 
and is metabolized to NAA and glutamate by glutamate car-
boxypeptidase II (GCPII) (Bzdega et  al., 1997). A  postmortem 
study has reported that NAA and NAAG levels are significantly 
lower in the brains of patients with major depressive disorder, 
schizophrenia, and bipolar disorder (Reynolds and Reynolds, 
2011). Alternatively, a clinical study using magnetic resonance 
spectroscopy has reported that the NAA level was significantly 
increased in adult patients with autism spectrum disorder com-
pared with that in the control group (Aoki et al., 2012). Therefore, 
these observations indicate that NAA synthetase Shati/Nat8l 
plays an important role in psychiatric disorders.
In the present study, we observed increased Shati/Nat8l mRNA 
expression in the dorsal striatum of mice that were exposed to 
forced swimming stress inducing behavioral despair. We pro-
duced genetically manipulated mice that specifically overex-
pressed Shati/Nat8l in the dorsal striatum (dS-Shati/Nat8l mice), 
using an adeno-associated virus (AAV) vector. We demonstrated 
that the dS-Shati/Nat8l mice exhibited depression-like behav-
iors and striatal mGluR3-related neuronal alterations. Our study 
suggests that Shati/Nat8l-regulated mGluR3 neurotransmission 
and the serotonergic neuronal system are associated with major 
depressive disorder.
Methods
Animals
Male C57Bl/6J strain mice (Nihon SLC) at 8 weeks of age (22–27 g) 
were used. The mice were housed in a regulated environment 
(25 ± 1°C; 50 ± 5% humidity) with a 12-hour-light/-dark cycle 
(lights on at 8:00 am). Food and water were available ad libi-
tum. All experiments followed the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and were 
approved by the Committee for Animal Experiments of the 
University of Toyama (A2015PHA-20).
Drugs
LY341495 and 2-(phosphonomethyl) pentanedioic acid (2-PMPA) 
were purchased from Tocris Bioscience (Ellisville) and dissolved 
in 0.125 M phosphate buffer (pH 8.0) and saline (0.9% NaCl), 
respectively. Fluvoxamine was obtained from Sigma-Aldrich 
and dissolved in saline. Other drugs were obtained from stand-
ard commercial sources. For behavioral experiments, the doses 
of LY341495 (0.3  mg/kg, i.p.) and fluvoxamine (10  mg/kg, i.p.) 
were determined on the basis of the maximum dose that did 
not affect the immobility time of wild-type mice in the forced 
swimming test. For neurochemical experiments, the dose of 
2-PMPA (30 mg/kg, i.p.) was determined as the amount that did 
not affect the locomotor activity in wild-type mice.
Production and Microinjection of the AAV Vector
The study design of the AAV vector was approved by the Board 
of Safety Committee for Recombination DNA Experiments 
of the University of Toyama (G2015PHA-12). The method used 
for the production and microinjection of AAV vector was pre-
viously reported (Krzyzosiak et al., 2010; Miyazaki et al., 2012). 
The AAV vector plasmids contained an expression cassette that 
included cDNA encoding either Shati/Nat8l (Shati: GenBank 
accession no. NM_001001985) or EGFP. The recombinant AAV-
Shati/Nat8l or AAV-Mock vectors were produced by co-trans-
fection of the AAV2 rep and AAV1 vp expression plasmid and 
pHelper (Agilent Technologies) in HEK293 cells. The suspension 
of AAV-Shati/Nat8l or AAV-Mock vectors (1010–1012 unit) was 
injected bilaterally into the dorsal striatum of anesthetized 
mice (0.5 mm anterior and 2.0 mm lateral from bregma, 3.5 mm 
below skull surface) using the coordinates of a mouse brain atlas 
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(Franklin and Paxinos, 2008). Three weeks after the microinjec-
tion, the mice were used for experiments.
Quantitative RT-PCR
Whole brains were removed and divided into 1-mm-thick sec-
tions using a mouse brain matrix (Neuroscience Idea). The tis-
sues of the dorsal striatum were collected with a 1-mm punch 
from the relevant section referencing to the plates of the mouse 
brain atlas (Franklin and Paxinos, 2008). The tissue samples were 
placed on dry ice and stored at -80°C until use. The quantita-
tive RT-PCR protocol and primers for Shati/Nat8l and 36B4 mRNA 
were previously reported (Miyamoto et al., 2014).
In Situ Hybridization
In situ hybridization was performed as previously reported 
(Sumi et al., 2015). Coronal sections of the paraformaldehyde-
fixed whole brain (20-μm thickness) were cut using a cryostat 
(Leica Biosystems). The coronal sections were hybridized to 
digoxigenin-labeled antisense and sense cRNA probes for Shati/
Nat8l (1133–1557 bp) using standard protocols. The staining sig-
nal of the developed image was observed using an AxioObserver 
Z1 (Carl Zeiss).
Locomotor Activity Test
We measured the locomotor activity of mice using previously 
published methods (Miyamoto et al., 2002, 2014). Briefly, a mouse 
was placed in a transparent acrylic cage with a black frosted 
Plexiglas floor (45 × 45 × 40  cm), and locomotion was measured 
for 60 minutes using digital counters with infrared sensors 
(SCANET MV-40; MELQUEST).
Forced Swimming Test
The forced swimming test was performed as previously 
described (Miyamoto et al., 2002). Briefly, individual mice were 
placed in a transparent polycarbonate cylinder (21 cm in diam-
eter × 22.5 cm high) containing water at 22°C to a depth of 18 cm. 
Mice were then forced to swim for 6 minutes. The duration of 
immobility was measured in 1-minute bins using a SCANET 
MV-40AQ (MELQUEST).
Tail Suspension Test
The tail suspension test was performed as previously described 
(Furukawa-Hibi et  al., 2010). Briefly, individual mice were sus-
pended by their tail for 6 minutes. The duration of immobility 
was recorded manually in 1-minute bins using a stopwatch.
Three-Chamber Social Interaction Test
The social testing apparatus comprised a rectangular, 3-cham-
bered box (Nadler et  al., 2004). Each chamber measured 
20 × 40 × 22  cm, and the dividing walls were made of clear 
Plexiglas with small square openings (5 × 3 × 3 cm) that allowed 
access to each chamber. Each individual mouse was habituated 
to the chamber without the wire cage for a single 20-minute ses-
sion. During trial 1, a novel object was placed in a wire cage in 
one side chamber and an empty wire cage was placed in the 
chamber on the other side. The subject mouse was placed in the 
middle chamber for 10 minutes and then allowed to explore the 
entire social test box for 10 minutes. The amount of time spent 
in the quadrant around each wire cage was recorded. During 
trial 2, another novel object was placed in the wire cage in one 
side chamber, and an intruder mouse (male C57Bl/6J strain) was 
placed in the wire cage in the chamber on the other side. The 
subject mouse was placed in the middle chamber for 10 min-
utes and then allowed to explore the entire social test box for 10 
minutes. The amount of time spent in the quadrant around each 
wire cage was recorded. A preference index was used to assess 
social interaction, that is, the ratio of the approach time either to 
the wire cage with the object (trial 1) or the intruder mouse (trial 
2) relative to the total approach time.
Measurement of NAA and NAAG
The measurement of NAA and NAAG by HPLC was performed as 
previously described (Reynold et al., 2005; Takanashi et al., 2012; 
Miyamoto et  al., 2014). Deproteinized samples for HPLC were 
applied to pretreated Bond Elut SAX anion exchange columns 
(Agilent Technologies) followed by extraction with phosphoric 
acid (85%).
Western Blotting
Western blotting was performed using standard protocols. Brain 
homogenates (20 μg total proteins) were separated using sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and blotted 
onto a polyvinylidene difluoride membrane. The membranes 
were incubated with primary antibodies, and the proteins were 
detected by horseradish peroxidase-conjugated secondary anti-
bodies and the ECL Prime kit (GE Healthcare). The anti-mGluR2/3 
antibody (#06-676, 1/1000) was obtained from Millipore. The anti-
NAAGS (#ab74284, 1/1000) and GCPII (#ab80554, 1/1000) antibod-
ies were obtained from Abcam. The antibody against GAPDH 
(#M171-3, 1/5000) was purchased from MBL.
In Vivo Microdialysis for 5-HT
We performed in vivo microdialysis as previously described 
(Miyamoto et al., 2014). The guide cannula was placed into the 
dorsal striatum of anesthetized mice (0.5  mm anterior and 
2.0 mm lateral from bregma, 3.5 mm below skull surface) accord-
ing to the mouse brain atlas (Franklin and Paxinos, 2008). The 
day following the operation, a dialysis probe (1-mm membrane 
length, EICOM) was inserted through the guide cannula and 
perfused with Ringer’s solution (147 mM NaCl, 4 mM KCl, and 
2.3 mM CaCl2) at a flow rate of 0.5 µL/min. The dialysates were 
collected in 12-minute fractions from the dorsal striatum and 
injected into an HPLC system equipped with a reversed-phase 
ODS column (PP-ODS; EICOM) connected to an electrochemi-
cal detector (EICOM). Three samples were used to establish the 
baseline levels of extracellular 5-HT.
Statistical Analysis
The data were expressed as the mean ± SEM. Statistical differences 
between 2 groups were determined using the Student’s t test. 
Statistical differences among values for individual groups were 
determined using ANOVA, followed by the Student-Newman-
Keuls posthoc test when the F value was significant (P < .05).
Results
Overexpression of Shati/Nat8l mRNA in the Dorsal 
Striatum
We initially investigated the association of Shati/Nat8l with 
depression-like behavior using normal wild-type mice. Two 
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hours after behavioral despair induced by forced swimming 
stress, which reflects a motivational decline, the expression lev-
els of Shati/Nat8l mRNA were increased in the dorsal striatum 
(P = .0115) but not in the prefrontal cortex (P = .0931), nucleus 
accumbens (P = .7421), or hippocampus (P = .2922) of the normal 
wild-type mice (Figure 1A). Following these results, we produced 
dS-Shati/Nat8l mice via the microinjection of AAV-Shati/Nat8l 
vectors into the dorsal striatum. Shati/Nat8l mRNA expres-
sion was greatly increased 9.9 ± 0.2-fold in the dorsal striatum 
(P = .0003) but not in the nucleus accumbens (P = .7228) of the 
dS-Shati/Nat8l mice compared with that in the control dS-Mock 
mice (Figure 1B). Furthermore, in situ hybridization detected the 
enhanced expression of Shat/Nat8l mRNA in the dorsal striatum 
of the dS-Shati/Nat8l mice (Figure 1C).
Behavioral Despair in the dS-Shati/Nat8l Mice
We performed various behavioral tests to assess the dS-Shati/
Nat8l mice. There were no differences in the total locomo-
tor activity counts between the dS-Mock and dS-Shati/Nat8l 
mice during a 60-minute observation period (dS-Mock mice, 
22821.8 ± 1045.7 counts; dS-Shati/Nat8l mice, 21570.9 ± 976.3 
counts; Student’s t test, P = .5154), suggesting that the motor 
function in the dS-Shati/Nat8l mice was unaffected. Further, we 
evaluated behavioral despair. The dS-Shati/Nat8l mice exhib-
ited a significant increase in immobility time during the forced 
swimming and tail suspension tests compared with the dS-
Mock mice (Figure  2A, D) (forced swimming test, P = .0228; tail 
suspension test, P = .0028).
Shati/Nat8l synthesizes NAA, which is then converted to NAAG, 
and NAAG acts as a neurotransmitter for mGluR3. Therefore, 
we examined the effect of a potent group II mGluR2/3 antago-
nist LY341495 on the behavioral despair of the dS-Shati/Nat8l 
mice. In both the forced swimming and tail suspension tests, the 
increased immobility time of the dS-Shati/Nat8l mice was attenu-
ated with the same dose of LY341495 administration (0.3 mg/kg, 
i.p. 30 minutes prior to each behavioral test) (Figure 2B, E) (forced 
swimming test, dS-Shati/Veh vs dS-Shati/LY; F3,42 = 3.318; P < .05; 
tail suspension test, dS-Shati/Veh vs dS-Shati/LY; F3,34 = 9.412; P 
< .01). Furthermore, we tested whether the behavioral despair of 
the dS-Shati/Nat8l mice responded to a common antidepressant, 
a selective serotonin reuptake inhibitor (SSRI), fluvoxamine. The 
administration of fluvoxamine (10 mg/kg, i.p. 30 minutes prior to 
each behavioral test) also attenuated the increased immobility 
time of the dS-Shati/Nat8l mice in the forced swimming and tail 
suspension tests (Figure 2C, F) (forced swimming test, dS-Shati/
Veh vs dS-Shati/Flu; F3,33 = 5.527; P < .05; tail suspension test, dS-
Shati/Veh vs dS-Shati/Flu; F3,31 = 18.97; P < .01).
Social Withdrawal in the dS-Shati/Nat8l Mice
We performed a 3-chamber social interaction test to examine 
sociability in mice (Nadler et  al., 2004; Nakatani et  al., 2009). 
In trial 1, the time spent exploring a novel object was signifi-
cantly longer than that spent in the empty wire cage for both 
the dS-Mock and dS-Shati/Nat8l mice (dS-Mock mice: novel 
object, 57.60 ± 3.38%; empty, 42.40 ± 3.38%; Student’s t test, 
P = .0038; dS-Shati/Nat8l mice: novel object, 55.66 ± 2.07%; empty, 
44.34 ± 2.07%; Student’s t test, P = .0006). However, there was no 
difference in the time spent exploring a novel object between 
the dS-Mock and dS-Shati/Nat8l mice. In trial 2, the dS-Mock 
mice spent significantly longer time with an intruder mouse 
than with the novel object (Figure 3A). In contrast, the dS-Shati/
Nat8l mice exhibited no difference in the time spent exploring 
the intruder mouse or the novel object (Figure  3A). Moreover, 
the time taken to approach the intruder mouse was significantly 
lower in the dS-Shati/Nat8l mice than that in the dS-Mock mice 
(Figure 3A).
We also assessed whether the social withdrawal of the dS-
Shati/Nat8l mice was attenuated by the administration of group II 
mGluR2/3 antagonist LY341495 or the antidepressant SSRI fluvox-
amine. The administration of LY341495 (0.3 mg/kg, i.p. 30 minutes 
prior to trial 2) or fluvoxamine (10 mg/kg, i.p. 30 minutes prior to 
trial 2) attenuated the decreased sociability of the dS-Shati/Nat8l 
mice (Figure 3B, C) (dS-Shati/Veh vs dS-Shati/LY, F3,34 = 4.236, P < .05; 
dS-Shati/Veh vs dS-Shati/Flu, F3,32 = 5.358, P < .01).
Thus, these pharmacological results suggest that depres-
sion-like behaviors, including behavioral despair and social 
withdrawal, in the dS-Shati/Nat8l mice are induced by the acti-
vation of group II mGluR-mediated neurotransmission and the 
dysfunction of the serotonergic neuronal system.
NAAG-mGluR3 Neurotransmission in the Dorsal 
Striatum of the dS-Shati/Nat8l Mice
To investigate mGluR3-mediated neurotransmission in the dor-
sal striatum of the dS-Shati/Nat8l mice, we measured the tis-
sue content of NAA and NAAG using HPLC. NAA exhibited a 
Figure 1. Shati/Nat8l mRNA expression in the dorsal striatum of mice that were 
exposed to forced swimming stress and of the dS-Shati/Nat8l mice. (A) Shati/
Nat8l mRNA in the dorsal striatum (dSTR) but not in the prefrontal cortex (PFC), 
nucleus accumbens (NAc), or hippocampus (HIP) was increased 2 hours after the 
forced swimming (FS) test (n = 6–8). *P < .05 vs Non-FS (Student’s t test). (B) Shati/
Nat8l mRNA was higher in the dSTR but not in the NAc of the dS-Shati/Nat8l 
mice compared with that in the dS-Mock mice (n = 3). **P < .01 vs dS-Mock (Stu-
dent’s t test). (C) In situ hybridization revealed that Shat/Nat8l mRNA was over-
expressed only in the dSTR of the dS-Shati/Nat8l mice. CTX, cortex; LV, lateral 
ventricle. Shati/Nat8l mRNA expression was measured by quantitative real-time 
RT-PCR and expressed relative to the expression of the housekeeping gene 36B4. 
The data are shown as the mean ± SEM.
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tendency to increase in the dS-Shati/Nat8l mice compared with 
the dS-Mock mice (dS-Mock mice, 2.973 ± 0.295  μmol/g tissue; 
dS-Shati/Nat8l mice, 3.738 ± 0.262 μmol/g tissue; Student’s t test, 
P = .0885). There was no change in NAAG between the dS-Mock 
and dS-Shati/Nat8l mice (dS-Mock mice, 0.151 ± 0.012 μmol/g tis-
sue; dS-Shati/Nat8l mice, 0.136 ± 0.010 μmol/g tissue; Student’s 
t test, P = .3852). However, the ratio of NAA to NAAG was signifi-
cantly lower in the dorsal striatum of the dS-Shati/Nat8l mice 
compared with that in the dS-Mock mice (Figure 4A) (P = .0070). 
In addition, we examined the expression levels of NAAG-related 
proteins, including NAAGS, mGluR2/3, and GCPII, in the dorsal 
striatum. The expression of NAAGS and mGluR2/3 was simi-
lar for the dS-Mock and dS-Shati/Nat8l mice (supplementary 
Figure 1A, B) (NAAGS, P = .6849; mGluR2/3, P = .6844). The expres-
sion of the GCPII, which is a glial ectoenzyme that hydrolyzes 
NAAG to glutamate and NAA, was significantly increased in 
the dS-Shati/Nat8l mice compared with the dS-Mock mice 
(Figure 4B) (P = .0047).
These results indicate that the release efficacy of NAAG into 
the synaptic cleft, which influences extracellular NAAG metabo-
lism, is upregulated in the dS-Shati/Nat8l mice.
mGluR3-Mediated Serotonergic Regulation in the 
Dorsal Striatum of the dS-Shati/Nat8l Mice
To confirm serotonergic neuronal dysfunction in the dS-Shati/
Nat8l mice, we measured 5-HT levels using in vivo microdialy-
sis. The basal levels of extracellular 5-HT in the dorsal striatum 
were significantly lower in the dS-Shati/Nat8l mice compared 
with the dS-Mock mice (Figure 4C) (P = .0064). This neurochemi-
cal result supports the observation that the behavioral abnor-
malities of the dS-Shati/Nat8l mice improved with fluvoxamine 
treatment.
To verify our findings on mGluR3-mediated serotoner-
gic regulation, we estimated the influence of mGluR3 activa-
tion on the serotonergic neuronal system in wild-type mice. 
A  single administration of a selective GCPII inhibitor 2-PMPA 
(30 mg/kg, i.p.) after pretreatment with vehicle for 6 days did not 
significantly affect extracellular 5-HT levels in the dorsal stria-
tum of wild-type mice (Figure 4D: Repeat Veh) (at 0 minutes vs 
120 minutes, P = .4118). Alternatively, wild-type mice that were 
repeatedly pretreated with 2-PMPA for 6  days (30  mg/kg/day, 
i.p.), showed a significant reduction in extracellular 5-HT levels 
Figure 2. Behavioral despair in the dS-Shati/Nat8l mice. (A) The immobility time in the forced swimming test was increased in the dS-Shati/Nat8l mice compared with 
the dS-Mock mice (n = 8–10). *P < .05 vs dS-Mock (Student’s t test). (B) The behavioral despair observed in the dS-Shati/Nat8l mice in the forced swimming test was atten-
uated by LY341495. Thirty minutes after treatment with vehicle (Veh) or LY341495 (LY, 0.3 mg/kg, i.p.), the immobility time was measured in the dS-Mock and dS-Shati/
Nat8l mice (n = 11–12). *P < .05 vs dS-Mock (Veh), #P < .05 vs dS-Shati (Veh) (ANOVA followed by Student-Newman-Keuls posthoc test). (C) The behavioral despair observed 
in the dS-Shati/Nat8l mice in the forced swimming test was attenuated by fluvoxamine. Thirty minutes after treatment with saline (Sal) or fluvoxamine (Flu, 10 mg/
kg, i.p.), the immobility time was measured in the dS-Mock and dS-Shati/Nat8l mice (n = 8–10). *P < .05 vs dS-Mock (Sal), #P < .05 vs dS-Shati (Sal) (ANOVA followed by 
Student-Newman-Keuls posthoc test). (D) The immobility time in the tail suspension test was increased in the dS-Shati/Nat8l mice compared with the dS-Mock mice 
(n = 12–15). **P < .01 vs dS-Mock (Student’s t test). (E) The behavioral despair observed in the dS-Shati/Nat8l mice in the tail suspension test was attenuated by LY341495. 
Thirty minutes after treatment with vehicle (Veh) or LY341495 (LY, 0.3 mg/kg, i.p.), the immobility time was measured in the dS-Mock and dS-Shati/Nat8l mice (n = 9–10). 
*P < .05 vs dS-Mock (Veh), ##P < .01 vs dS-Shati (Veh) (ANOVA followed by Student-Newman-Keuls posthoc test). (F) The behavioral despair observed in the dS-Shati/Nat8l 
mice in the tail suspension test was attenuated by fluvoxamine. Thirty minutes after treatment with saline (Sal) or fluvoxamine (Flu, 10 mg/kg, i.p.), the immobility 
time was measured in the dS-Mock and dS-Shati/Nat8l mice (n = 8–9). **P < .01 vs dS-Mock (Sal), ##P < .01 vs dS-Shati (Sal) (ANOVA followed by Student-Newman-Keuls 
posthoc test). The data are shown as the mean ± SEM.
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in the dorsal striatum 120 minutes after the seventh adminis-
tration compared with that before administration (Figure  4D: 
Repeat 2-PMPA) (at 0 minutes vs 120 minutes, P = .0010) without 
an effect on basal 5-HT levels (6-day vehicle repeated pretreat-
ment, 0.275 ± 0.019 pg/μL; 6-day 2-PMPA repeated pretreatment, 
0.296 ± 0.023 pg/μL).
These findings suggest that the continuous enhancement of 
mGluR3 neurotransmission induced by extracellular NAAG ele-
vation suppresses serotonergic neuronal function in the dorsal 
striatum.
Discussion
In the present study, the dS-Shati/Nat8l mice exhibited both 
behavioral despair and social withdrawal, and these depression-
like behaviors were successfully attenuated by the administra-
tion of SSRI fluvoxamine. The dS-Shati/Nat8l mice also exhibited 
decreased extracellular 5-HT levels in the dorsal striatum, and 
the administration of group II mGluR2/3 antagonist LY341495 
ameliorated depression-like behaviors in the dS-Shati/Nat8l 
mice. In our previous study, NAA and NAAG levels were signifi-
cantly increased by the infusion of an AAV-Shati/Nat8l vector 
into the nucleus accumbens (Miyamoto et al., 2014), whereas in 
the present study, there was no significant change in NAA or 
NAAG levels in the dorsal striatum of the dS-Shati/Nat8l mice. 
Notably, the conversion efficiency of NAA to NAAG was altered 
and the extracellular NAAG peptidase GCPII, but not NAAGS, was 
overexpressed in the dorsal striatum of the dS-Shati/Nat8l mice. 
Thus, NAAG-mGluR3 neurotransmission could be activated by 
the increased extracellular NAAG levels in the dorsal striatum 
of the dS-Shati/Nat8l mice. Alternatively, considering the pos-
sibility that NAAG is not a direct endogenous agonist for mGluR3 
(Chopra et al., 2009), the extracellular glutamate levels may be 
increased because of NAAG metabolism by GCPII, and there-
fore glutamate neurotransmission may be activated. However, 
the continuous activation of NAAG-mGluR3 neurotransmission 
by GCPII inhibitor in the wild-type mice induced serotonergic 
neuronal dysfunction in the dorsal striatum. Our observations 
suggest that the Shati/Nat8l-associated system in the dorsal 
striatum regulates depression-like behaviors via mGluR3-medi-
ated serotonergic suppression.
Postmortem NAA levels are significantly lower in the stria-
tum of the brains of patients with major depressive disorder 
(Reynolds and Reynolds, 2011). In the present study, depression-
like behaviors induced by Shati/Nat8l-overexpression in the 
dorsal striatum were observed; however, there were no con-
siderable changes in NAA levels in the brain region. This dis-
crepancy may be because of the chronic treatment of human 
patients with antidepressants leading to decreased NAA lev-
els. Regardless, NAA metabolism in the striatum appears to be 
involved in major depressive disorder. In addition, in clinical 
studies, major depressive disorder has been reported to be asso-
ciated with polymorphisms in the mGluR3 gene GRM3 (Tsunoka 
et al., 2009). Thus, functional alterations of the NAA synthetase 
Shati/Nat8l and its downstream mGluR3 neurotransmission 
might be the pathological aspects of major depressive disor-
der. The activation of mGluR3 neurotransmission proposed by 
us is supported by much evidence, which have demonstrated 
that group II mGluR2/3 antagonists ameliorate depression-like 
behaviors in animal models (Bespalov et al., 2008; Engers et al., 
2015; Podkowa et al., 2016; Chaki 2017).
In major depressive disorder, the cerebrospinal fluid levels of 
5-hydroxyindoleacetic acid, a metabolite of 5-HT, are low (Asberg 
et  al., 1976; Banki et  al., 1981), and such patients have higher 
5-HT transporter potentials than healthy individuals (Meyer 
et al., 2004). SSRIs are generally prescribed as antidepressants in 
clinics. Therefore, the decrease of 5-HT levels in the brain is con-
sidered a pathological aspect of major depressive disorder. In the 
present study, both behavioral despair and social withdrawal, 
which reflect the symptoms of major depressive disorder, were 
induced by Shati/Nat8l-overexpression in the dorsal striatum. 
These phenomena were ameliorated by the administration of 
antidepressant SSRI or group II mGluR2/3 antagonist. Moreover, 
we observed decreased extracellular 5-HT levels in the dorsal 
striatum of the dS-Shati/Nat8l mice and decreased 5-HT levels 
in the dorsal striatum induced by continuous mGluR3 activation 
in the wild-type mice. Taken together, our observations suggest 
that Shati/Nat8l in the dorsal striatum regulates depression-
like behaviors by controlling serotonergic neuronal function via 
mGluR3 neurotransmission.
The beneficial effects of group II mGluR2/3 antagonist on 
depression-like behaviors are associated with the serotonergic 
Figure 3. Social withdrawal in the dS-Shati/Nat8l mice. (A) In trial 2 of the 3-chamber social interaction test, the dS-Shati/Nat8l mice were not more interested in 
the stranger mouse than the dS-Mock mice (n = 14–16). ††P < .01 vs dS-Mock (Novel object), *P < .05 vs dS-Shati (Stranger mouse) (Student’s t test). (B) Social withdrawal 
observed in the dS-Shati/Nat8l mice in the 3-chamber social interaction test was attenuated by LY341495. Thirty minutes after the treatment with vehicle (Veh) or 
LY341495 (LY, 0.3 mg/kg, i.p.), the approach time was measured in the dS-Mock and dS-Shati/Nat8l mice (n = 9–10). *P < .05 vs dS-Mock (Veh), #P < .05 vs dS-Shati (Veh) 
(ANOVA followed by Student-Newman-keuls posthoc test). (C) Social withdrawal observed in the dS-Shati/Nat8l mice in the 3-chamber social interaction test was 
attenuated by fluvoxamine. Thirty minutes after treatment with saline (Sal) or fluvoxamine (Flu, 10 mg/kg, i.p.), the approach time was measured in the dS-Mock and 
dS-Shati/Nat8l mice (n = 8–9). **P < 0.01 vs dS-Mock (Sal), ##P < .01 vs dS-Shati (Sal) (ANOVA followed by Student-Newman-Keuls posthoc test). The data are shown as the 
mean ± SEM.
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neuronal system in the medial prefrontal cortex (Fukumoto 
et  al., 2014; Pehrson and Sanchez 2014; Chaki 2017). However, 
functional roles of the dorsal striatum in depression remain 
unclear. The dorsal striatum receives projections from the 
serotonergic neurons in the dorsal raphe nucleus and sup-
plies GABAergic projections to the serotonergic neurons in the 
dorsal raphe nucleus; this neuronal circuit is associated with 
reward-seeking and motivational behaviors (Michelsen et  al., 
2007; Nakamura 2013; Pollak Dorocic et al., 2014). Furthermore, 
there are distinct types of GABAergic interneurons in the dor-
sal striatum (Tepper et al., 2010). Therefore, group II mGluR2/3 
antagonists may directly or indirectly activate the seroton-
ergic neuronal system in the dorsal striatum via stimulating 
the GABAergic interneurons or projections to the dorsal raphe 
nucleus. The synaptic mechanism of mGluR2/3-mediated sero-
tonergic neuronal modulation in the dorsal striatum should be 
investigated to elucidate the neuronal mechanism of the dorsal 
striatum in major depressive disorder.
Incidentally, impaired social interaction is one of the core 
symptoms of autism spectrum disorder. Individuals with autism 
spectrum disorder exhibit impaired 5-HT-mediated neuronal 
function (Huang and Santangelo, 2008). Furthermore, proton 
magnetic resonance spectroscopy has revealed that NAA levels 
were higher in the brains of patients with autism spectrum dis-
order than in the control group (Aoki et  al., 2012). Both social 
withdrawal and 5-HT depletion were induced by Shati/Nat8l-
overexpression in the dorsal striatum. Although the detailed 
pathology of autism spectrum disorder is unclear, the serotoner-
gic neuronal dysfunction indirectly affected by Shati/Nat8l may 
be associated with autism spectrum disorder.
In conclusion, the present study is the first to demonstrate 
that the overexpression of NAA synthetase Shati/Nat8l in the dor-
sal striatum induces behavioral despair, social withdrawal, and 
extracellular 5-HT depletion. Our results indicate that the regula-
tion of motivation and social interaction via the striatal mGluR3-
mediated control of the serotonergic neuronal system plays an 
important role in the pathogenesis of major depressive disorder. 
Therefore, Shati/Nat8l and its downstream influence on mGluR3 
neurotransmission may be potential new targets for the develop-
ment of pharmacotherapies for major depressive disorder.
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